School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, UK.
Br J Pharmacol. 2012 Apr;165(8):2411-3. doi: 10.1111/j.1476-5381.2011.01731.x.
The further characterization of the orphan GPCR GPR18 conducted by McHugh et al. in this issue of the British Journal of Pharmacology has generated a pharmacological profile that raises some interesting questions about the nomenclature of this receptor and may also prompt some questions about the pharmacological definition of the classical cannabinoid receptors, CB(1) and CB(2) . LINKED ARTICLES This article is a commentary on McHugh et al., pp. 2414-2424 of this issue and is part of a themed section on Cannabinoids in Biology and Medicine. To view McHugh et al. visit http://dx.doi.org/10.1111/j.1476-5381.2011.01497.x. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
麦克休等人在本期《英国药理学杂志》上对孤儿 G 蛋白偶联受体 GPR18 的进一步研究,提供了一个药理学特征,这引发了一些关于该受体命名的有趣问题,也可能对经典大麻素受体 CB(1) 和 CB(2) 的药理学定义提出一些质疑。
相关文章 本文是对麦克休等人在本期杂志上发表的关于 GPR18 的研究的评论,也是生物与医学中的大麻素这一专题的一部分。要查看麦克休等人的文章,请访问 http://dx.doi.org/10.1111/j.1476-5381.2011.01497.x。要查看该专题中的其他文章,请访问 http://dx.doi.org/10.1111/bph.2012.165.issue-8。要查看生物与医学中的大麻素的第一部分,请访问 http://dx.doi.org/10.1111/bph.2011.163.issue-7。